Literature DB >> 16871467

The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.

M Hendset1, T Haslemo, I Rudberg, H Refsum, E Molden.   

Abstract

In therapeutic drug monitoring (TDM) practice of psychotropic agents, it is common to summarize plasma concentrations of parent drugs and metabolites when these are considered equipotent. However, there is no clear definition of the term equipotent and one should be aware that metabolites referred to as equipotent in the literature could display several-fold differences in affinities toward target proteins. The fact that the parent drug and metabolite may have different abilities to penetrate the blood-brain-barrier further complicates the picture. Potential differences in brain distribution imply that various metabolite/drug ratios representing the same total concentration in plasma reflect different active concentrations in the brain. Plasma metabolite/drug ratios could differ extensively according to metabolic phenotype and administration route. An example is risperidone where the plasma metabolite/drug ratio is 30-fold lower in cytochrome P450 2D6 poor metabolizers compared to ultrarapid metabolizers, and four-fold lower after intramuscular compared to oral administration. As risperidone is more lipophilic and less effluxed by P-glycoprotein in the blood-brain-barrier than the active metabolite 9-hydroxyrisperidone, one might speculate that patients with high plasma metabolite/drug ratios obtain lower active concentrations in the brain. However, the relative drug-metabolite brain distribution needs to be quantified in humans to clarify to what degree drug and metabolite plasma levels reflect active brain concentrations. The present review illustrates the complexity of active metabolites in TDM with focus on amitriptyline, clomipramine, doxepin, imipramine, fluoxetine, venlafaxine and risperidone, all psychotropic drugs where target plasma concentration ranges are based on the sum of parent drug and metabolite. In addition, perspectives on the possibility of using distribution- and activity-weighted plasma concentrations are provided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871467     DOI: 10.1055/s-2006-946701

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  12 in total

1.  Development of controlled-release matrix tablet of risperidone: influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailability.

Authors:  Amir Badshah; Fazal Subhan; Khalid Rauf; Nadeem Irfan Bukhari; Kifayatullah Shah; Samiullah Khan; Zia Ahmed; Ihsanullah Khan
Journal:  AAPS PharmSciTech       Date:  2011-04-15       Impact factor: 3.246

2.  Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.

Authors:  Felice Pasini; Carmen Barile; Donatella Caruso; Yasmina Modena; Anna Paola Fraccon; Laura Bertolaso; Daniela Menon; Francesca La Russa; Giorgio Crepaldi; Antonio Bononi; Roberto Spezzano; Roberto Padrini; Giuseppe Corona; Milena Gusella
Journal:  Invest New Drugs       Date:  2018-06-28       Impact factor: 3.850

Review 3.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

4.  Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.

Authors:  Terhi Launiainen; Ilpo Rasanen; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2010-04-30       Impact factor: 2.686

5.  Synthesis and μ-Opioid Activity of the Primary Metabolites of Carfentanil.

Authors:  Fu-Lian Hsu; Andrew J Walz; James M Myslinski; Li Kong; Michael G Feasel; Tyler D P Goralski; Tim Rose; Nicholas J Cooper; Neil Roughley; Christopher M Timperley
Journal:  ACS Med Chem Lett       Date:  2019-10-16       Impact factor: 4.345

6.  Doxepin concentrations in plasma and cerebrospinal fluid.

Authors:  Robert Schomburg; Daniela Remane; Klaus Fassbender; Hans H Maurer; Jörg Spiegel
Journal:  J Neural Transm (Vienna)       Date:  2011-02-25       Impact factor: 3.575

7.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

8.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

9.  Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.

Authors:  Magnhild Hendset; Monica Hermann; Hilde Lunde; Helge Refsum; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2007-09-09       Impact factor: 2.953

10.  Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia.

Authors:  Gwen McCaffrey; Melissa J Seelbach; William D Staatz; Nicole Nametz; Carolyn Quigley; Chris R Campos; Tracy A Brooks; Thomas P Davis
Journal:  J Neurochem       Date:  2008-07-21       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.